Table I.
Anticancer activity of P. linteus compounds.
| Compound | Target cells | Biological effects | Reference |
|---|---|---|---|
| APPL | Macrophage | Increased production of NO, activation of PTK and PKC | 24 |
| APPL | Melanoma | Inhibition of cell adhesion and invasion, inhibition of metastasis in mice | 25 |
| PBP | Colon cancer | Inhibition of proliferation and colony formation, cell cycle arrest at G2/M, decrease in cyclin B1; induction of apoptosis, decrease in Bcl-2, increase in cytochrome c | 27 |
| PGC | Sarcoma | Inhibition of tumor growth in mice | 15 |
| PLP | Melanoma | Inhibition of tumor growth and pulmonary metastasis in mice | 23 |
| PPC | Splenocytes | Induction of proliferation of B-cells | 26 |
| Macrophage | Induction of production of IL-1β, IL-6, TNF-α and NO | ||
| NK-cells | Enhanced cytotoxicity | ||
| Hispolon | Epidermoid | Inhibition of proliferation; induction of apoptosis, activation of caspase-3 | 21 |
| Breast and bladder cancer | Inhibition of proliferation, cell cycle arrest at G2/M, up-regulation of p21; induction of apoptosis, activation of caspase-7, down-regulation of MDM2 | 28 | |
| Phellifuropyranone A, Meshimakobnol A and B | Melanoma and lung cancer | Inhibition of proliferation | 29 |
APPL, acid polysaccharide; PBP, protein-bound polysaccharide; PGC, protein-glucan complex; PLP, polysaccharide; PPC, polysaccharide-protein complex.